News

Apr 06 2016
Lymphoma Canada is preparing submissions to the pan­Canadian Oncology Drug Review (pCODR) for: Ibrutinib (Imbruvica) for patients with previously untreated CLL for whom fludarabine-based treatment is considered inappropriate and Venetoclax (ABT-199) for patients with relapsed/refractory CLL

Pages